The efficay of paclitaxel combined with gemcitabine for patients with anthracycine-resistant metastatic breast Cancer

VernacularTitle:紫杉醇联合吉西他滨治疗蒽环类耐药晚期乳腺癌临床观察
Author: Wang JIAN
Publication Type:Journal Article
Keywords: Breast neoplasms; Drug therapy; Paclitaxel; Gemcitabine
From: Chinese Journal of Primary Medicine and Pharmacy 2011;18(18):2455-2456
CountryChina
Language:Chinese
Abstract: ObjectiveTo evaluate the clinical efficacy and toxicity of the regimen of paclitaxel combined with gemcitabine for anthracycine-resistant metastatic breast cancer. MethodsThirty patients with anthracycine-resistant metastatic breast cancer were enrolled in the study: paclitaxel 135mg/m2 infusion on day 1; Gemcitabine 850mg/m2 infusion on day 1,8 ,and administered in three weeks cycle. The clinical efficacy was evaluated every two cycles. ResultsOf all thirty patients qualified for efficacy analysis and among them CR 3 cases( 10％ ) ,PR 11 cases (36.7 ％ ), SD 11 cases ( 36.7％ ), and PD 5 cases ( 16.7％ ), with an overall response rate of 46.7％. The median TTP and overall survival in those 30 patients was 7.1 and 15.6 months. The main toxicities with grade 3 and 4 were hypoleucocytosis in 10 patients(30.0％ ) ,thrombocytopenia in 4 patients( 13.3％ ). ConclusionThe regimen of paclitaxel combined with gemcitabine was effective,well-tolerated scheme in the anthracycine-resistant metastatic breast cancer.